医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd & Zhangjiajie Tourism Group Co. Ltd Entered a Strategic Cooperation Agreement

2016年01月01日 AM08:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

As at January 1, 2016, Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd (“Zhangjiajie Jinchi”), a wholly-owned subsidiary of Jinchi Biotech Ltd ( “Jinchi Biotech”)(NSX:JCB), entered a strategic cooperation agreement (the “Strategic Cooperation Agreement”) with Zhangjiajie Tourism Group Co. Ltd (“Zhangjiajie Tourism Group”, stock code:000430).

Zhangjiajie Jinchi and Zhangjiajie Tourism Group will cooperate on marketing, promoting, advertising and training, and share advertisement resources and launch a new exquisite tourism route: Yangjiajie, Baofeng Lake and Zhangjiajie Giant Salamander Science Museum.

Zhangjiajie Tourism Group is a state-owned holding company listed on the Shenzhen Stock Exchange with tourism resources development, tourism infrastructure construction, high-tech development in tourism industry, and security investment consultancy services as its main business. In 2014, Zhangjiajie Tourism Group achieved annual operating income about AUD$ 104,350,000 (RMB 484,009,400) and received nearly 5 million tourists, among which Yangjiajie and Baofeng Lake attracted 339,300 and 562,400 tourists respectively.

The Strategic Cooperation Agreement, which is mainly focused on Zhangjiajie tourism industry, can help promote Zhangjiajie Giant Salamander Science Museum to worldwide tourists and enhance brand effect and advertising effect. This agreement is expected to bring Zhangjiajie Giant Salamander Science Museum more than 200,000 tourists, which may greatly increase ticket proceeds and product sales revenue in 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151231005058/en/

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究